Physician profile
Edwin E Cabahug
NPI 1972055952
$2,543.02
in general payments reported to CMS, 2019-2025
18 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.34 · 2022: $728 · 2023: $225 · 2024: $481 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $375.75 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $293.25 | 2022-2025 | Arexvy, Shingrix, Penmenvy |
| Amgen INC. | $276.48 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Novo Nordisk INC | $266.13 | 2021-2025 | Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $194.79 | 2022-2025 | Camzyos |
| Astrazeneca Pharmaceuticals Lp | $152.78 | 2022-2024 | Andexxa, Breztri |
| Biohaven Pharmaceutical Holding Company Ltd. | $144.14 | 2022 | |
| Gilead Sciences, INC. | $140.00 | 2025 | Epclusa |
| Bayer Healthcare Pharmaceuticals INC. | $124.79 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $124.79 | 2022 | |
| Dynavax Technologies Corporation | $121.10 | 2022-2025 | Heplisav-B |
| Abbott Laboratories | $113.28 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $81.47 | 2021-2025 | Pifeltro |
| Dexcom, INC. | $49.56 | 2022-2025 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $42.15 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $16.37 | 2023 | Apretude |
| Coloplast Corp | $13.34 | 2023 | Altis |
| Phadia US INC. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Cabahug listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.